Study to Determine the Safety, Maximum Tolerated Dose, Pharmacokinetics of Sorafenib (BAY43-9006)

Carcinoma Clinical Trial

Official title:

Phase I Study to Determine the Safety, Maximum Tolerated Dose, PK of BAY43-9006 in Repeated Cycles of 18 Days On/3 Days Off in Combination With Paclitaxel and Carboplatin Chemotherapy in Patients With Advanced, Refractory Solid Tumors

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00941863
• Other study ID #: 100375
• Status: Completed
• Phase: Phase 1
• First received: June 12, 2009
• Last updated: January 20, 2016
• Start date: July 2002
• Est. completion date: April 2008

Study information

• Verified date: January 2016
• Source: Bayer
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Food and Drug Administration
• Study type: Interventional

Clinical Trial Summary

The primary objective of the study was to define the safety profile and maximum tolerated dose (MTD) of sorafenib tablets in combination with carboplatin and paclitaxel chemotherapy in patients with advanced, refractory solid tumors.

The secondary objectives were evaluation of pharmacokinetics (PK) and tumor response of these patients being treated with sorafenib in combination with paclitaxel and carboplatin.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 158
• Est. completion date: April 2008
• Est. primary completion date: May 2005
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Histologically confirmed solid tumors

• Evaluable disease

• Eastern Cooperative Oncology Group (ECOG) 0 or 1

• Life expectancy minimum 12 weeks

Exclusion Criteria:

• Congestive heart failure

• Serious arrhythmias

• Coronary artery disease (CAD) or ischemia

• HIV (human immunodeficiency virus)

• Hepatitis B or C

• Serious active infection

• Metastatic brain or meningeal tumors

Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Carcinoma

Intervention

Drug:
• Sorafenib 100 mg (50-mg tablet)
Sorafenib (Nexavar, BAY43-9006) 100 mg twice daily (50-mg tablet)
• Sorafenib 200 mg (50-mg tablet)
Sorafenib (Nexavar, BAY43-9006) 200 mg twice daily (50-mg tablet)
• Sorafenib 400 mg (50-mg tablet)
Sorafenib (Nexavar, BAY43-9006) 400 mg twice daily (50-mg tablet)
• Sorafenib 400 mg (200-mg tablet)
Sorafenib (Nexavar, BAY43-9006) 400 mg twice daily (200-mg tablet)
• Sorafenib 400 mg (Expansion)
Sorafenib (Nexavar, BAY43-9006) 400 mg twice daily (200-mg tablet) expansion

Locations

Country	Name	City	State
n/a

Sponsors (2)

Lead Sponsor	Collaborator
Bayer	Onyx Pharmaceuticals

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Serious Adverse Events	25 of 119 participants from the Expansion Phase, were still on the treatment as of 31 May 2005. Of these, 6 subjects were continuing to receive sorafenib in combination with carboplatin and/or paclitaxel and 19 subjects were receiving single-agent sorafenib. The responses reported in these participants were from start of treatment until 18 Sep 2008.	From start of treatment until 18 Sep 2008, up to 6 years	Yes
Other	Other Adverse Events	Frequency Threshold for reporting Other Adverse Events: 5%. 25 of 119 participants from the Expansion Phase, were still on the treatment as of 31 May 2005. Of these, 6 subjects were continuing to receive sorafenib in combination with carboplatin and/or paclitaxel and 19 subjects were receiving single-agent sorafenib. The responses reported in these participants were from start of treatment until 18 Sep 2008.	From start of treatment until 18 Sep 2008, up to 6 years	Yes
Primary	Maximum Tolerated Dose (MTD) of Sorafenib in Combination With Paclitaxel and Carboplatin	MTD was determined by testing increasing doses up to 400 mg twice daily (bid) on dose escalation cohorts 1 to 3 with 3 patients each. MTD reflects highest dose of drug that did not cause an unacceptable side effect (= Dose Limiting Toxicity (DLT) in more than 30% of patients; e.g., hematologic toxicities like Common Toxicity Criteria (CTC) Grade 4 Neutropenia in specific conditions, platelets < 25,000 cells/mL; specific non-hematologic/biochemical toxicities CTC Grade 3 or 4; additionally, any toxicity considered by the investigator severe enough was designated a DLT); CTC Version 2 were used.	21 days	Yes
Primary	Participants With Hematological and Biochemical Toxicities	Participants are considered at risk for toxicity if participants had a lab measurement for the toxicity >= National Cancer Institute Common Toxicity Criteria (NCI CTC) Grade 3 as defined by the NCI CTC version 2; SGOT: Serum Glutamic-Oxaloacetic Transaminase, SGPT: Serum Glutamic-Pyruvic Transaminase, AST: Aspartate Aminotransferase, ALT: Alanine Aminotransferase.	Start of treatment until death or within 14 days last study drug intake	Yes
Secondary	Tumor Response	Tumor Response (= Best Overall Response) of a subject was defined as the best tumor response (confirmed Complete Response (CR), confirmed Partial Response (PR), Stable Disease (SD), or Progressive Disease (PD)) observed during trial period assessed according to the Response Evaluation Criteria in Solid Tumors (RECIST) criteria. CR was defined as disappearance of tumor lesions, PR was defined as a decrease of at least 30% in the sum of tumor lesion sizes, SD was defined as steady state of disease, PD was defined as an increase of at least 20% in the sum of tumor lesions sizes.	From start of treatment until progression or death occurs assessed every 6 weeks.	No
Secondary	Area Under the Curve From Time 0 to 12 Hours Post-dose (AUC 0-12) Start From Day 2 of Cycle 1	The AUC is a measure of systemic drug exposure, which is obtained by collecting a series of blood samples and measuring the concentrations of drug in each sample. A plot of concentration vs time after dosing is created, and the area under this curve is calculated by standard methods (eg, trapezoidal rule) to provide a measure of how much drug was in the bloodstream following dosing.	At day 2 in study	No
Secondary	Maximum Concentration (CMAX) Start From Day 2 of Cycle 1	Cmax refers to the highest plasma concentration of drug reached after dosing. It is obtained by collecting a series of blood samples after dosing, and analyzing them for drug content by a sensitive and specific analytical method. The highest measured concentration is referred to as the Cmax.	At day 2 in study	No
Secondary	Time of Maximum Concentration (TMAX) Start From Day 2 of Cycle 1	Tmax refers to the time after dosing when a drug attains its maximum concentration in the blood. It is obtained by collecting a series of blood samples at various times after dosing, and measuring them for drug content. The time corresponding to the highest measurable concentration (Cmax) is referred to as Tmax.	At day 2 in study	No

External Links

•   Click here and search for drug information provided by the FDA.
•   Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product.